Zhejiang University FAP CAR-DC trial, end-stage dilated cardiomyopathy

This document is a new clinical trial registration entry added to ClinicalTrials.gov, the US-based public registry operated by the National Library of Medicine. The trial investigates FAP CAR-DC cell therapy as a treatment for end-stage dilated cardiomyopathy and is sponsored by Zhejiang University. Trial registration includes protocol details, eligibility criteria, anticipated enrollment, and study locations.\n\nFor patients with end-stage dilated cardiomyopathy, this trial represents a potential novel therapeutic approach using CAR-DC cell technology. Healthcare providers treating cardiomyopathy patients should be aware of this emerging trial for referral considerations. The registration serves transparency and public health notification purposes rather than imposing regulatory compliance obligations.